The purpose of the study is to see whether a higher radiation dose improves overall survival. Participants will be randomly assigned to receive either the standard radiation dose or a higher dose, then all will continue with the same durvalumab treatment. The study follows patients for several months, checking how long they live, how the cancer responds, any side effects, and how they feel in daily life.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The purpose of the study is to identify the optimal amount of the medication and to evaluate its ability to shrink or stop the growth of the cancer (anti‑tumour activity). The research is conducted as a phase II trial, meaning it is designed to test different dose levels for safety and effectiveness after initial safety has been shown.

Participants receive a series of injections of the study drug into the tumor at scheduled visits, followed by regular medical examinations, imaging scans, and questionnaires that assess symptoms and overall well‑being. The study continues until the treatment plan is completed or until the disease progresses, with ongoing monitoring to record any side effects and changes in the tumor size.

The purpose of the study is to find out which of these treatments best prevents death, heart attack (also called myocardial infarction) or stroke during the first year after the heart event while also keeping serious bleeding low. Participants will take the assigned tablet once daily for up to 12 months and will attend scheduled visits to monitor their health.

During the year, participants will have regular visits where doctors check health, ask about any new problems, and record any occurrences of heart attack, stroke, death, or major bleeding. This information is used to compare the safety and effectiveness of the medicines.

The purpose of the study is to assess how safe the new injection is and how it changes the activity of a clotting protein called factor XI (FXI) over a 16‑week period. Participants will be randomly assigned to receive one of two hidden doses of the injection or the placebo, and all will receive the open‑label tablet. Visits will include simple blood draws to measure FXI activity and routine safety checks such as checking for bleeding or other side effects.

Throughout the trial, researchers will watch for any bleeding events, record any adverse experiences, and perform standard laboratory tests and vital‑sign measurements. Blood samples will also be taken at several time points to see how the drug behaves in the body and whether the immune system produces any antibodies against it.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

The main aim of the study is to evaluate how often the tumors shrink, known as an objective response. Participants receive the study drug in treatment cycles that repeat every few weeks, with regular visits for physical exams, blood tests, and imaging scans to check the size of the tumor and overall health.

Tumor shrinkage is classified as a complete response when the cancer disappears, a partial response when the tumor size decreases by a significant amount, or stable disease when the tumor does not grow or shrink much. Throughout the trial, doctors monitor for adverse events, which are side effects or any unwanted medical problems, and record any that are serious or lead to stopping the treatment.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the trial is to determine whether this combined therapy is safe and practical for this age group. Participants first undergo screening and baseline assessments, then attend a series of therapy sessions during which the medication is taken in capsule form. After the treatment phase, they continue with follow‑up visits to monitor any side effects and to observe changes in mood and daily functioning, while a separate group receives the same therapy at a later time for comparison.

The purpose of the study is to determine whether this therapy improves heart performance and is safe compared with standard care. Participants are randomly assigned to receive either the insulin‑based regimen plus usual treatment or usual treatment alone. The study treatment is given for up to two days while patients remain in the hospital, during which doctors watch heart function, blood pressure, kidney function and any side effects using a thin tube called a catheter (via pulmonary artery catheterization) and regular blood tests. After leaving the hospital, patients are checked again for about six weeks to see if they needed extra heart‑support devices and how well the heart and kidneys are working.

Safety monitoring includes continuous observation of heart rhythm, blood pressure, and the amounts of other heart‑support medicines used. The trial is open label, meaning both the care team and the participants know which treatment is being given, and it is designed as a small pilot to gather early information about the new approach.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

The aim is to find out whether the nasal dose of the study drug reduces the pain measured by the Premature Infant Pain Profile‑Revised during the first 30 seconds after the eye speculum is placed. Infants are randomly assigned to receive either the study drug or the placebo, then undergo the standard eye screening while pain scores and basic vital signs are recorded. After the exam the infants continue to be observed for a short period to monitor any breathing changes, oxygen needs, crying, sleep, or other reactions before returning to regular care.

The purpose of the study is to assess the long‑term safety and clinical benefit of the medication. Participants will take the granules by mouth each day for an extended period and will attend regular visits where doctors will check how they are feeling and perform simple tests.

During the visits, several simple assessments are done: a muscle‑function questionnaire called NSAD, a walking speed test over ten meters known as the 10MWT, a breathing test that measures how much air can be exhaled called FVC, an upper‑limb function test named PUL 2.0, a walking distance test over one hundred meters called 100MTT, and a blood test that measures a protein called CK which indicates muscle damage. These checks help researchers understand how the medication affects muscle strength, movement, and overall health over time.

The purpose of this phase II study is to find out whether taking sirolimus after surgery can lead to a lasting reduction in the size of the affected lip and a change in the color of the birthmark, while also checking safety and how the condition impacts quality of life. Participants will start the medication after their surgical procedure and will be followed for several years, with periodic visits to measure the lip’s size with a simple ruler, to assess color changes using a four‑step scale, and to complete questionnaires that ask about daily activities and comfort.

The primary aim is to evaluate how well this combination works in controlling the disease. Participants receive the injection and the capsule on a repeated schedule, typically every few weeks, and are followed for several months with regular doctor visits, blood tests, and imaging to check for disease activity and any side effects. The study continues until a predefined number of treatment cycles are completed or if a participant experiences significant toxicity that requires stopping the therapy.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

The main goal of the study is to see if the medication is safe and how well it reaches the CNS and influences a brain chemical known as 4-hydroxy-2-nonenal. Over a period of about 12 weeks, participants will take the assigned pill daily and attend regular check‑ups. At the beginning and end of the study, a small amount of fluid surrounding the brain and spinal cord, called CSF, may be collected through a thin needle to measure the level of the drug’s breakdown product AD-835 and the amount of the brain chemical. Simple brain scans using 31P-MRS may be performed to assess the brain’s energy use, and blood samples will be analyzed with LC‑MS. Laboratory tests such as ELISA, TBARS, and measurement of MDA will be used to evaluate the brain chemical levels.

Participants are randomly assigned to either the active drug or placebo and will take the tablets daily for roughly 18 months alongside their cancer treatment. Heart function is measured at the start and at the end of the study using CMR, a special type of MRI that visualizes the heart. The primary assessment is the change in LVEF, which indicates how well the left side of the heart pumps blood. Additional evaluations include GLS, a measure of how the heart muscle stretches during beats, and blood tests for NT-proBNP and the high‑sensitivity cardiac injury markers hs‑TnI and hs‑TnT.

Healthy volunteers will receive each of the three injections (the two anesthetics and the placebo) in separate study periods, with the order chosen at random and neither the participants nor the staff knowing which injection is given at any time. After each injection, a small device will apply electrical stimulation to create a temporary area of increased pain sensitivity called hyperalgesia, and participants will rate the pain they feel. Additional tests will use a cuff that inflates around the arm to measure the pressure at which pain is first felt and the pressure that can be tolerated, known as cuff-pressure algometry. Throughout the study, blood pressure, heart rate, any side effects and adverse events will be recorded, and each participation period lasts only a few days.

The purpose of the study is to evaluate the safety and how well participants tolerate a step‑up dosing schedule of 25 mg, then 50 mg, and finally 100 mg of the drug. Volunteers will take the tablet at each dose level for a short period, after which they will provide saliva samples to check for the amount of virus present and have blood drawn to measure immune responses such as the number of CD4 T cells that react to the virus using a test called ELISPOT, as well as levels of specific antibodies, including IgG. The study proceeds without complex procedures, allowing participants to continue their normal daily activities while being monitored for any side effects.

The study uses a step-by-step treatment plan. Each person will have periods with atorvastatin, periods with placebo, and a period with no study treatment. The order of these periods is arranged by chance. During the study, muscle symptoms are checked over time to compare how they change during each period.

The study is designed to help understand statin-associated muscle symptoms, which are muscle problems that some people notice while taking statin medicines such as atorvastatin. It also looks at whether some symptoms may be nocebo or misattributed, meaning they are felt as real symptoms but may not be caused by the medicine itself.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

The study has more than one part. In one part, EIK1005 is given by itself. In another part, EIK1005 is given with pembrolizumab. Participants may take the study tablet on a regular schedule and receive pembrolizumab through a vein during clinic visits. During the study, doctors watch for side effects and other health changes, and treatment may be adjusted as needed. The study also includes people with tumors that are MSI-H or dMMR, which are tumor features linked to problems in how cancer cells repair damage in their genetic material.

EIK1005 is also called a Werner helicase inhibitor. A helicase is a protein that helps cells handle and copy genetic material, and this medicine is designed to block that protein. The trial is planned to continue over several years while safety and dose information are collected.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The study lasts about 24 weeks. Participants are assigned by chance to receive either lerodalcibep or placebo, and neither the family nor the study team knows which one is given during the study. The medicine is given once a month, and study visits are spread over the treatment period. Doctors also check general health, growth, and development, and watch for side effects and other safety concerns.

The main purpose of the study is to find out whether lerodalcibep is safe and effective for lowering LDL-C in children and adolescents with this inherited cholesterol disorder. Other blood fats and some body changes related to growth and hormones are also followed during the study.

People in the study receive ifinatamab deruxtecan over time during regular treatment visits. The study is open-label, which means both the study team and the participant know which treatment is being given. The course of the study includes treatment and follow-up visits to watch for side effects and to see how long any benefit lasts. The study also looks at how long people live without the cancer getting worse and how many side effects happen during treatment.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.